Literature DB >> 12225876

Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration.

Masashi Takanashi1, Hideo Mori, Kunimasa Arima, Yoshikuni Mizuno, Nobutaka Hattori.   

Abstract

Deposition of hyperphosphorylated tau (p-tau) has been observed in several neurodegenerative diseases. The six isoforms of tau are divided into two main groups including three repeat (3R) and four repeat (4R) microtubule-binding domains. Using quantitative RT-PCR method and immunohistochemistry with phosphorylation dependent anti-tau antibody (AT8), we investigated the expression level of tau mRNA isoforms in the frontal cortex and globus pallidus of patients with progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) to determine whether altered expression patterns of tau mRNA isoforms correlate with p-tau accumulation. The 4R/3R ratios in frontal cortices of CBD and globus pallidus of PSP and CBD were significantly higher than the control (P<0.05). There was no correlation between the expression patterns of tau mRNA isoforms and p-tau accumulation. Our findings suggest that neurodegeneration of PSP and CBD could be regulated by alternative splicing of tau mRNA to yield high 4R/3R ratio. In addition, the lack of correlation between the expression pattern of tau mRNA isoforms and p-tau accumulation suggests that not only alternative splicing of tau mRNA, but also other factors such as post-transcriptional or translational modifications may play a role in the pathogenesis of specific neurodegeneration in PSP and CBD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225876     DOI: 10.1016/s0169-328x(02)00382-0

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  13 in total

Review 1.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

2.  Identification of Parkinson's disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson's disease patients.

Authors:  Rowena J Keyser; Ekow Oppon; Jonathan A Carr; Soraya Bardien
Journal:  J Neural Transm (Vienna)       Date:  2011-02-23       Impact factor: 3.575

3.  Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies.

Authors:  Teresa Rodriguez-Martin; Mariano A Garcia-Blanco; S Gary Mansfield; Andrew C Grover; Michael Hutton; Qingming Yu; Jianhua Zhou; Brian H Anderton; Jean-Marc Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-17       Impact factor: 11.205

Review 4.  The neurogenetics of atypical parkinsonian disorders.

Authors:  Brent L Fogel; Mary C Clark; Daniel H Geschwind
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 5.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

6.  Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients.

Authors:  A Lladó; M Ezquerra; C Gaig; R Sánchez-Valle; E Tolosa; J L Molinuevo
Journal:  J Neural Transm (Vienna)       Date:  2007-07-30       Impact factor: 3.575

7.  Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study.

Authors:  J E Tobin; J C Latourelle; M F Lew; C Klein; O Suchowersky; H A Shill; L I Golbe; M H Mark; J H Growdon; G F Wooten; B A Racette; J S Perlmutter; R Watts; M Guttman; K B Baker; S Goldwurm; G Pezzoli; C Singer; M H Saint-Hilaire; A E Hendricks; S Williamson; M W Nagle; J B Wilk; T Massood; J M Laramie; A L DeStefano; I Litvan; G Nicholson; A Corbett; S Isaacson; D J Burn; P F Chinnery; P P Pramstaller; S Sherman; J Al-hinti; E Drasby; M Nance; A T Moller; K Ostergaard; R Roxburgh; B Snow; J T Slevin; F Cambi; J F Gusella; R H Myers
Journal:  Neurology       Date:  2008-05-28       Impact factor: 9.910

Review 8.  Functional MAPT haplotypes: bridging the gap between genotype and neuropathology.

Authors:  Tara M Caffrey; Richard Wade-Martins
Journal:  Neurobiol Dis       Date:  2007-05-05       Impact factor: 5.996

9.  Advances in tau-based drug discovery.

Authors:  Wendy Noble; Amy M Pooler; Diane P Hanger
Journal:  Expert Opin Drug Discov       Date:  2011-08-01       Impact factor: 6.098

10.  Variation in tau isoform expression in different brain regions and disease states.

Authors:  Elisa Majounie; William Cross; Victoria Newsway; Allissa Dillman; Jana Vandrovcova; Christopher M Morris; Michael A Nalls; Luigi Ferrucci; Michael J Owen; Michael C O'Donovan; Mark R Cookson; Andrew B Singleton; Rohan de Silva; Huw R Morris
Journal:  Neurobiol Aging       Date:  2013-02-19       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.